OXFORD, England, October 31, 2011 /PRNewswire/ -- - Research and development agreement signed with Mayo Clinic - Oxford BioMedica plc ("Oxford BioMedica"

OXFORD, England, October 18, 2011 /PRNewswire/ -- -- Third ocular product partnered with Sanofi approved to enter clinical development -- Oxford BioMedica

OXFORD, England, June 22, 2011 /PRNewswire/ -- - RetinoStat(R) Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat(R) is safe and well-tolerated at one month following treatment. RetinoStat(R) is a novel gene-based treatment for neovascular "wet" age-related macular degeneration (AMD), designed and developed by Oxford BioMedica using the Company's proprietary LentiVector(R) gene delivery technology.

OXFORD, United Kingdom, June 6, 2011 /PRNewswire/ -- Oxford BioMedicaplc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc.

OXFORD, England, May 23, 2011 /PRNewswire-FirstCall/ -- - Six-Month Data From Third Cohort Presented at ASGCT 14th Annual Meeting - - Highest Efficacy Results to Date With 43% Average Motor Function Improvement - Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin(R) for the treatment of Parkinson's disease (PD) were presented at the American Society of Gene & Cell Therapy (ASGCT) 14th Annual Meeting held in Seattle, USA by Professor Stephane Palfi, Principal Investigator at the Henri Mondor Hospital in Paris, on Saturday 21 May 2011. Highlights of third cohort at six months (2x dose, enhanced administration) - Average motor function1 improvement of 43%, with a maximum of 61% in one patient; - Patient diary data2 show an increase in functional "ON" time (when PD symptoms are not present) of approximately 3 hours; - Patient diar